Cancer Research

No matter what type of chemotherapy you attack a tumor with, many cancer cells resort to the same survival tactic: They start eating themselves. This autophagy process happens when two proteins pair up and switch it on this process, according to a new paper.

"This gives us a therapeutic avenue to target autophagy in tumors," says Brigham Young University chemistry professor Josh Andersen. "The idea would be to make tumors more chemo-sensitive. You could target these proteins and the mechanism of this switch to block autophagy, which would allow for lower doses of chemotherapy while hopefully improving patient outcomes."


It's not a movie about zombies, but it's a Halloween nightmare - at night while we sleep unaware, something deadly grows and spreads quickly.

In a surprise finding, Weizmann Institute of Science researchers have found that nighttime is the right time for cancer to grow and spread in the body. Their findings suggest that administering certain treatments in time with the body’s day-night cycle could boost their efficiency.
Researchers are investigating a possible association between breast implants and a form of lymphoma that may develop tumors at a later stage. The researchers conclude that breast implants can cause a new subtype of the rare yet malignant lymphoma known as anaplastic large cell lymphoma (ALCL).

Worldwide there have been 71 documented cases of patients with ALCL in which researchers suspected breast implants to be the cause. ALCL is normally found in the lymph nodes, as well as in skin, lung, liver and soft tissue, but not usually in the breast. 

A few years ago there was concern that poor people did not have access to the best health care because of high cost, but two new papers find that spending is actually too high.

The first study examines recent trends in spending and use of oral cancer drugs. They find that average spending on the 47 available oral oncolytics — cancer medication taken specifically by mouth — increased from $940 million in the first quarter of 2006 to $1.4 billion by the third quarter of 2011. 


A research group has discovered that AIM - Apoptosis Inhibitor of Macrophage - a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice liver cells. 

This discovery may lead to a therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer and the third most common cause of cancer deaths.


Breast cancer is the second leading cause of cancer death in women, which is why so many medical professionals encourage women to get mammograms. But the tests are not very accurate: only a minority of suspicious mammograms actually leads to a cancer diagnosis.

Bad results lead to needless worry for women and their families—not to mention the time, discomfort and expense of additional tests, including ultrasounds and biopsies. 


Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces clinical trial findings showing that trastuzumab (Herceptin) should remain the standard of care for this cancer.


Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.


Within the first 5 years after the birth of a child, women are considered at an increased risk of developing metastatic breast cancer.

Why that happens has been considered a puzzle but the fact remains that women diagnosed with postpartum breast cancer have a decreased disease free survival time compared to women that have never given birth.

The aggressive tendency of postpartum breast cancer suggests that the post-birth breast environment promotes tumor metastasis. A new study in the Journal of Clinical Investigation, suggests that dying tumor cells in postpartum breast tissue promote metastatic disease.


Ovarian cancer is the most deadly gynecological kind, it claims the lives of more than 50% of women who are diagnosed

Ovarian cancer is often diagnosed late and develops a resistance to chemotherapy but new insight into why may lead to better diagnosis and treatment.